FeesSafety
Pluang+

Kyntra Bio cuts royalty payments by $60M, plans Phase 3 trial for anemia drug in early 2027

Company Fundamentals
16 Nov 2026, 23:05 WIB
GlobeNewsWire
View Source
Neutral
Kyntra Bio cuts royalty payments by $60M, plans Phase 3 trial for anemia drug in early 2027

Kyntra Bio restructured its royalty financing, reducing future payments by $60 million, leaving only $15 million owed. The company plans to start a pivotal Phase 3 trial of roxadustat for anemia in lower-risk myelodysplastic syndromes (LR-MDS) patients in early 2027, pending a strategic partnership or capital raise. It discontinued two prostate cancer drug developments due to poor efficacy, saving over $20 million in expenses. With $44.1 million in cash and equivalents, Kyntra Bio expects funding into 2028.

Kyntra Bio's third quarter 2026 financial results and business update provide context for the health sector's market activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 17, 2026 03:31 WIB: out of 150 priced US health-sector stocks, 31 rose and 118 fell today. Notably, SLS traded at USD 7.36 with a 1-day change of -6.42% and a typical hold time of 5 days, ARWR was priced at USD 44.78 down 6.28%, and SANA at USD 1.90 down 6.19% with a 27-day hold time and 100% buy order activity.

More News

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney Q4 outlook strong with 50%+ EPS growth and streaming as key driver

Disney's fiscal Q4 report, due November 17, is expected to show strong growth with analysts forecasting over 50% earnings per share (EPS) growth and more than 12% revenue increase. Streaming revenue rose 11% last quarter with margins hitting double d...

Company Fundamentals
Bullish
2 hours ago
Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox launches Australia realm on AWS for local DDI management and security.

Infoblox has launched a new Australia realm on Amazon Web Services (AWS) in the Sydney region, providing Australian government agencies and enterprises a local option for managing DNS, DHCP, and IP address management (DDI) with enhanced security. Thi...

Market News
Bullish
2 hours ago
European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
3 hours ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
4 hours ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App